## BACKGROUND. Women treated with tamoxifen for breast cancer are at increased risk of endometrial cancer. This study examines the experience at Roswell Park Cancer Institute (RPCI) with women diagnosed with both endometrial carcinoma (EC) and breast carcinoma (BC) to determine the risk and stage
Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen
✍ Scribed by Turbiner, Julia; Moreno-Bueno, Gema; Dahiya, Sonika; Sánchez-Estevez, Carolina; Hardisson, David; Prat, Jaime; Oliva, Esther; Palacios, José
- Book ID
- 109887670
- Publisher
- Nature Publishing Group
- Year
- 2008
- Tongue
- English
- Weight
- 445 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0893-3952
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Among 1,420 patients with thoracic esophageal carcinoma, 85 (6.1 %) had synchronous gastric carcinoma. Seventy-two patients (84.7%) underwent esophagectomy . Their operative mortality and prognosis were similar to those without gastric carcinoma. Among them, 25 patients, of whom the majority had adv
## Abstract Endometrial carcinoma (EC) is the most common extracolonic tumor associated with hereditary nonpolyposis colorectal cancer (HNPCC). HNPCC increases the risk of EC compared to the general population. Patients with HNPCC have a better prognosis than patients with common sporadic colorecta
## Background: Tamoxifen commonly is used as adjuvant therapy for all stages of breast carcinoma. however, several studies have suggested an association between the use of tamoxifen in breast carcinoma patients and the subsequent development of endometrial carcinoma. the objective of this study was